KBA1412
Oncology (likely solid tumors)
Phase 1Active
Key Facts
About Kling Biotherapeutics
Kling Biotherapeutics leverages a clinically validated B cell immortalization technology to discover novel targets and antibodies from elite patient responders. Its dual-platform approach, Kling-Select and Kling-Evolve, has generated a pipeline including a first-in-class CD9 antibody (KBA1412) currently in Phase 1 for oncology. The company is backed by venture capital, led by an experienced team, and its foundational technology has a proven track record, having contributed to the discovery of the marketed RSV antibody nirsevimab (Beyfortus™).
View full company profileTherapeutic Areas
Other Oncology (likely solid tumors) Drugs
| Drug | Company | Phase |
|---|---|---|
| Undisclosed TiNA-based Immunotherapy | AilseBio | Pre-clinical |